Sacubitril & Valsartan Tablets 24/26MG – WONMADA 50 Tablets

WONMADA 50 – A New Standard in Heart Failure Therapy, Unlike Traditional ACE Inhibitors or ARBs.

WONMADA 50 – The unique combination of Sacubitril & Valsartan Tablets 24/26MG (Sacubitril + Valsartan 50 mg – 25 mg + 26 mg) offers a breakthrough approach in managing heart failure with reduced ejection fraction (HFrEF):
Sacubitril – A neprilysin inhibitor that enhances levels of beneficial peptides, promoting blood vessel relaxation and sodium excretion.
Valsartan – An angiotensin II receptor blocker (ARB) that counteracts vasoconstriction and helps lower blood pressure.
Together, they provide a synergistic effect to reduce the heart’s workload, enhance cardiac performance, and improve overall outcomes in heart failure patients.

Key Benefits of Sacubitril & Valsartan Tablets – WONMADA 50
✅ Dual Mechanism for Heart Failure Management – Combines neprilysin inhibition and angiotensin receptor blockade, addressing both volume overload and vascular resistance for optimal heart failure treatment.
✅ Reduces Hospitalization – Clinical studies have demonstrated that this therapy lowers the chances of heart failure-related deaths and hospital admissions more effectively than ACE inhibitors, leading to better patient outcomes and an improved quality of life.
✅ Superior Symptom Management – Effectively alleviates common heart failure symptoms such as tiredness, fluid retention, and breathlessness, helping patients lead a more energetic and independent life.

Recommended By Specialists:
👨‍⚕️Cardiologists: For the management of Heart Failure with Reduced Ejection Fraction (HFrEF) and as a first-line therapy for patients not adequately controlled on ACE inhibitors or ARBs.
👨‍⚕️General Practitioners: For stable heart failure patients requiring optimized therapy to improve exercise tolerance and reduce fatigue, edema, and risk of cardiovascular death.

INDICATIONS:
✅ Heart failure (prevent hospitalization)
✅ Heart failure with reduced ejection fraction (HFrEF)